Welcome to our dedicated page for Kraig Biocraft Laboratories In SEC filings (Ticker: KBLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), alongside AI-generated summaries where such filings are available. While no specific SEC filings are listed in the provided data, investors commonly look to documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and ownership reports on Form 3 and Form 4 to understand a company’s operations and governance.
For a company like Kraig Biocraft Laboratories, which publicly emphasizes recombinant spider silk technology, selective breeding of silkworm hybrids such as BAM-1 and BAM-1 Alpha, and multi-facility production in Southeast Asia, formal filings can offer structured disclosure on business risks, intellectual property, production infrastructure, and financing. They may also provide additional detail on material agreements, collaborations, and any significant events that complement the operational milestones described in the company’s news releases.
On Stock Titan, when KBLB filings are available from EDGAR, they can be presented with AI-powered summaries that highlight key sections and help explain complex language. This can make it easier to identify information about production expansion plans, use of proceeds from any offerings, or governance topics such as executive compensation and board structure, without reading every page in full.
In addition, ownership and insider transaction reports, such as Form 4 filings when present, can be useful for tracking changes in holdings by directors, officers, or significant shareholders. By combining raw documents with AI explanations, this page aims to help users review Kraig Biocraft Laboratories’ regulatory history and disclosures more efficiently whenever filings are available.
Kraig Biocraft Laboratories’ annual report shows it is still pre-revenue and recorded a net loss of $3,623,353 for the year ended December 31, 2025, slightly higher than the prior year’s loss of $3,398,939. The auditor’s report includes a going concern warning due to recurring losses, a stockholders’ deficit of $7,998,958, and an accumulated deficit of $56,709,072. At year-end, the company held cash and cash equivalents of $1,790,236 against current liabilities of $10,445,245, resulting in a working capital deficit of $8,576,604. To bolster liquidity, Kraig entered a $10 million Standby Equity Purchase Agreement, allowing it to sell common shares at its discretion. The business continues to focus on developing recombinant spider silk fibers via genetically engineered silkworms, with production centered in Vietnam and ongoing R&D aimed at improved fiber performance and silkworm robustness.
Kraig Biocraft Laboratories, Inc. disclosed that it has been featured in a cover article of the March 2026 issue of National Geographic. The company notes that this March 2026 issue is currently available only in select markets and is expected to be distributed nationally in the coming weeks.
Kraig Biocraft Laboratories (KBLB) reported Q3 results with revenue of $0 and a net loss of $1,509,566 for the quarter; the nine‑month net loss was $2,835,732. Operating expenses were $1,433,888 in Q3 and $2,652,125 year‑to‑date.
As of September 30, 2025, the Company had cash of $1,565,692, a working capital deficiency of $8,544,784, and a stockholders’ deficit of $7,956,077. Management disclosed that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Financing activity included $1,925,702 raised under a Standby Equity Purchase Agreement and common shares issued for services valued at $834,600. The Company sold 111 ounces of gold year‑to‑date for $369,992 in proceeds, recognizing a $160,896 realized gain; remaining gold was carried at $494,478. Related‑party note payable was $1,567,000 with $426,589 in year‑to‑date interest expense. Accounts payable and accrued expenses – related party were $8,004,099. Class A shares outstanding were 1,080,852,130 as of November 12, 2025; 1,076,244,777 were outstanding as of September 30, 2025.